Behavioral characteristics of dopamine D5 receptor knockout mice

Transcriptomic analysis of the human habenula in schizophrenia

Pathophysiology of many neuropsychiatric disorders, including schizophrenia (SCZD), is linked to habenula (Hb) function. While pharmacotherapies and deep brain stimulation targeting the Hb are emerging as promising therapeutic treatments, little is known about the cell type-specific transcriptomic organization of the human Hb or how it is altered in SCZD. Here we define the molecular neuroanatomy of the human Hb and identify transcriptomic changes in individuals with SCZD compared to neurotypical controls. Utilizing Hb-enriched postmortem human brain tissue, we performed single nucleus RNA-sequencing (snRNA-seq; n=7 neurotypical donors) and identified 17 molecularly defined Hb cell types across 16,437 nuclei, including 3 medial and 7 lateral Hb populations, several of which were conserved between rodents and humans. Single molecule fluorescent in situ hybridization (smFISH; n=3 neurotypical donors) validated snRNA-seq Hb cell types and mapped their spatial locations. Bulk RNA-sequencing and cell type deconvolution in Hb-enriched tissue from 35 individuals with SCZD and 33 neurotypical controls yielded 45 SCZD-associated differentially expressed genes (DEGs, FDR < 0.05), with 32 (71%) unique to Hb-enriched tissue. eQTL analysis identified 717 independent SNP-gene pairs (FDR < 0.05), where either the SNP is a SCZD risk variant (16 pairs) or the gene is a SCZD DEG (7 pairs). eQTL and SCZD risk colocalization analysis identified 16 colocalized genes. These results identify topographically organized cell types with distinct molecular signatures in the human Hb and demonstrate unique genetic changes associated with SCZD, thereby providing novel molecular insights into the role of Hb in neuropsychiatric disorders.

One Sentence Summary

Transcriptomic analysis of the human habenula and identification of molecular changes associated with schizophrenia risk and illness state.

Constitutive activity of the dopamine (D5 ) receptor, highly expressed in CA1 hippocampal neurons, selectively reduces CaV 3.2 and CaV 3.3 currents

BACKGROUND AND PURPOSE

Ca_V 3.1-3 currents differentially contribute to neuronal firing patterns. Ca_V 3 are regulated by G protein-coupled receptors (GPCRs) activity, but information about Ca_V 3 as targets of the constitutive activity of GPCRs is scarce. We investigate the impact of D₅ recpetor constitutive activity, a GPCR with high levels of basal activity, on Ca_V 3 functionality. D₅ recpetor and Ca_V 3 are expressed in the hippocampus and have been independently linked to pathophysiological states associated with epilepsy.

EXPERIMENTAL APPROACH

Our study models were HEK293T cells heterologously expressing D₁ or D₅ receptor and Ca_V 3.1-3, and mouse brain slices containing the hippocampus. We used chlorpromazine (D₁ /D₅ inverse agonist) and a D₅ receptor mutant lacking constitutive activity as experimental tools. We measured Ca_V 3 currents and excitability parameters using the patch-clamp technique. We completed our study with computational modelling and imaging technique.

KEY RESULTS

We found a higher sensitivity to TTA-P2 (Ca_V 3 blocker) in CA1 pyramidal neurons obtained from chlorpromazine-treated animals compared with vehicle-treated animals. We found that Ca_V 3.2 and Ca_V 3.3-but not Ca_V 3.1-are targets of D₅ receptor constitutive activity in HEK293T cells. Finally, we found an increased firing rate in CA1 pyramidal neurons from chlorpromazine-treated animals in comparison with vehicle-treated animals. Similar changes in firing rate were observed on a neuronal model with controlled Ca_V 3 currents levels.

CONCLUSIONS AND IMPLICATIONS

Native hippocampal Ca_V 3 and recombinant Ca_V 3.2-3 are sensitive to D₅ receptor constitutive activity. Manipulation of D₅ receptor constitutive activity could be a valuable strategy to control neuronal excitability, especially in exacerbated conditions such as epilepsy.